Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US Gastrointestinal Intergroup RTOG 98-11 Phase 3 Trial

Journal Article · Fri Nov 15 04:00:00 EST 2013 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2013.07.035· OSTI ID:22267929

Moughan, Jennifer ^[1]; Ajani, Jaffer A. ^[2]; Pedersen, John E. ^[3]; Winter, Kathryn A. ^[1]; Benson, Al B. ^[4]; Thomas, Charles R. ^[5]; Mayer, Robert J. ^[6]; Haddock, Michael G. ^[7]; Rich, Tyvin A. ^[8]; Willett, Christopher G. ^[9]

---

1. Radiation Therapy Oncology Group, Philadelphia, Pennsylvania (United States)
2. The University of Texas MD Anderson Cancer Center, Houston, Texas (United States)
3. Cross Cancer Institute, Edmonton, Alberta (Canada)
4. Northwestern University, Chicago, Illinois (United States)
5. Knight Cancer Institute/Oregon Health and Science University, Portland, Oregon (United States)
6. Dana-Farber Cancer Institute, Boston, Massachusetts (United States)
7. Mayo Clinic Cancer Center, Rochester, Minnesota (United States)
8. University of Virginia, Charlottesville, Virginia (United States)
9. Duke University, Durham, North Carolina (United States)

Purpose: The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin. The intent of the current analysis was to determine the impact of tumor node (TN) category of disease on survival (DFS and OS), colostomy failure (CF), and relapse (local-regional failure [LRF] and distant metastases [DM]) in this patient group. Methods and Materials: DFS and OS were estimated univariately by using the Kaplan-Meier method, and 6 TN categories were compared by the log–rank test (T2N0, T3N0, T4N0, T2N1-3, T3N1-3, and T4N1-3). Time to relapse and colostomy were estimated by the cumulative incidence method, and TN categories were compared using Gray's test. Results: Of 682 patients, 620 were analyzable for outcomes by TN category. All endpoints showed statistically significant differences among the TN categories of disease (OS, P<.0001; DFS, P<.0001; LRF, P<.0001; DM, P=.0011; CF, P=.01). Patients with the poorest OS, DFS, and LRF outcomes were those with T3-4N-positive (+) disease. CF was lowest for T2N0 and T2N+ (11%, 11%, respectively) and worst for the T4N0, T3N+, and T4N+ categories (26%, 27%, 24%, respectively). Conclusions: TN category of disease has a statistically significant impact on OS, DFS, LRF, DM, and CF in patients treated with CCRT and provides excellent prognostic information for outcomes in patients with anal carcinoma. Significant challenges remain for patients with T4N0 and T3-4N+ categories of disease with regard to survival, relapse, and CF and lesser challenges for T2-3N0/T2N+ categories.

• OSTI ID: 22267929
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 87; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
COMPARATIVE EVALUATIONS
MITOMYCIN
PATIENTS
RECTUM